@toki_wo_koe 2013年のLoDoCo試験でも言われてましたが、同じ人ですかね? https://t.co/C6kljQpmMb
Low dose of Colchicine 0.5mg in patient with Chronic Coronary Disease, demonstrated fewer Cardiovascular event, HR: 0.33 (95% CI 0.18-0.59) P= 0.001, [ARR: 10.7%], However, (LoDoCo) trial enrolled only 532 patients and was not placebo-controlled. 📊📉 https
3/5 3️⃣ #cvCCS LoDoCo 2013 ⚖️ 🚻532 CCS on GDMT ↗️0.5mg OD ↘️placebo 🔚 ⬇️ACS+CVA+🫀arrest✅ (Mainly by⬇️ACS event) 🚨Limitation: sample size, blinding, lack of placebo, LTF #CardioEd @JACCJournals https://t.co/ELsGmKQnfv
@GermanSalgado22 @osmarperse @gonzaeperez @drpablocorral @JoseJuanatey @jpcostabel @valentin_vioj Lo antecedía el LoDoCo con solo 532 pacientes. https://t.co/k3pMI650I3
7/ Colchicine group had a significantly lower composite rate of ACS (out-of-hospital cardiac arrest, noncardioembolic ischemic stroke (p<0.001). *Study design requires result caution interpretation (open-label, no randomization, no placebo). https://t
E duas boas dicas: 1- fazendo conta no NEJM, sem precisar pagar pelo acesso, se ganha direito à leitura de 3 artigos por mês; 2- esse artigo é muito semelhante a um publicado em 2012 na JACC, que pode ser lido aqui! Boa leitura, cardiolovers <3 (4/4) h
11/14 Clinical EVIDENCE of colchicine so far: a) patients w/ stable CAD in the LoDoCo trial (HR 0.33, 95% CI 0.18 to 0.59, p<0.001; NNT 11); mainly driven by reduction in ACS https://t.co/zJguxHILZD https://t.co/BkuyT3B6M2
colchicine is a worthy candidate drug for future secondary prevention trials in patients with stable coronary disease. #lodoco2 #cardiotwitter #MedTwitter https://t.co/Dgtg2OVGkn
@drpatrickholmes @kamleshkhunti @mmamas1973 @AbdTahrani @docwas @amibanerjee1 @TheBHF @ADA_DiabetesPro Doesn’t clearly make sense tbh why 0.3mg works ... and then combined with earlier 0.5mg colchicine findings (2ndry prevention trial) its a bit mixed/mess
Will LoDoCo2 confirm LoDoCo? Is low-cost, widely available colchicine effective in CAD pts? Will see at #ESCCongress @escardio @SABOURETCardio @mirvatalasnag @Ahmed43101178 Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease https://t.c
@GoutGroup You reference colchicine like it's a thing of the past, while it's not the case. IMHO it's more effective then NSAID's as first line at the right time (within flare initiation). It also has some remarkable effects such as secondary CVD prevent
Teníamos alguna evidencia con Colchicina? si, en estudios experimentales en animales y luego en ensayos clínicos, inicialmente en enfermedad crónica. https://t.co/lsMUAtFa9W
@jdflaysakier #COLCOT confirme les données d'études plus anciennes sur la maladie coronaire stable et de taille inférieure qui montraient des résultats similaires https://t.co/UCK9YBm6So
@skathire @DrNadolsky Another one that found almost the same just with stable coronary disease. If I see the results properly, it's more effective then statins. https://t.co/2Jmryp8cwp
@pnatarajanmd @JAMACardio Does this help explain the results of the LoDoCo trial (https://t.co/8wK48Au9AJ)? Or was that all just anti-inflammatory effect of colchicine?
(A quick aside: blockage of this innate immune response is likely why the following studies showed positive results: - CANTOS - using IL-1 https://t.co/JlIGuuq65u - LoDoCo - using colchicine https://t.co/bdUIOqezRI ) /7
RT @psufka: Looks like pretty impressive data to me. Wondering why this isn't considered on a more widespread basis. https://t.co/E28dDhuKC…
Looks like pretty impressive data to me. Wondering why this isn't considered on a more widespread basis. https://t.co/E28dDhuKC3 @drjohnm https://t.co/wMFSjXsyue
Thanks! Looks like a great read. I'm such a cardio geek since my bypass. I read all the articles you post. If you see Dr Aslam tell him hi. https://t.co/OpRX8f4kfq
@Destinations247 also check out https://t.co/Qh9r1P0lYm
@isa75012 yes @BeckySueToo tweeted this earlier https://t.co/4OOOhnb5Er #rheumjc
Colchicine to prevent MI: https://t.co/43gJxwGRS8 #rheumjc
@normancanter @medicalaxioms citation for Lo do co study https://t.co/LOqPtA3gDm [Mark-google tells me "lo do co" is also part of Denver!]
@skathire @brianedwardsmd 9% absolute reduction in ACS with colchicine in stable coronary disease http://t.co/0e7E0fCfLX
@epinephrinerx @23041988 จริงๆ evidence หลังๆ ดูดีครับ ในแง่ CAD http://t.co/VmlIHZUtxu http://t.co/tI5Drb0IGO http://t.co/fM0nBgLr4S
#Colchicine data to prevent CAD (NNT~10) is 2 yrs old but no one seems to be integrating evidence into practice. Why? http://t.co/Q0DjcMtKur
#Colchicine data to prevent CAD (NNT~10) is 2 yrs old but no one seems to be integrating evidence into practice. Why? http://t.co/Q0DjcMtKur
#Colchicine data to prevent CAD (NNT~10) is 2 yrs old but no one seems to be integrating evidence into practice. Why? http://t.co/Q0DjcMtKur
Colchicine #Cardiology http://t.co/sNXRAp1zmu
" Low-dose colchicine for secondary prevention of cardiovascular disease" http://t.co/Mf2AVEuxjJ
狭心症の二次予防に対するコルヒチンの有効性 http://t.co/v7LpiRHtrv
Tomorrow's journal club: LoDoCo (another good cardiology trial acronym). Should we use colchicine in stable CAD? http://t.co/TSTScfh6hE
Low-dose colchicine for secondary preventi... [J Am Coll Cardiol. 2013] - PubMed - NCBI http://t.co/gWZpdo7Lmt
コルヒチン少量による心血管イベント抑制:古い薬でもみつかる新たな役割 http://t.co/R8AFeL7cyI
http://t.co/nmV3adTo8m ¿Colchicina en prevención 2ª CV? ECA demasiado pequeño con efecto demasiado grande
Kan det virkelig passe: Gammel cellegift reduserer risikoen for nytt hjerteinfarkt. NNT = 9!!! #MI #kolkisin http://t.co/26LEE2S4YZ
@HyleAnzi atherosclerotic plaque that leads to an increase in coronary artery disease. This is the source: http://t.co/yPAKxyRt 3